IBI Ag is an Israeli agri-biotech company pioneering a platform that uses single-domain antibodies (nanobodies) to create highly selective biological insecticides. Adapted from human therapeutics and optimized for agriculture, its products introduce new modes of action that protect high-value crops from both sucking and chewing pests while sparing beneficial species. The firm positions its technology as a lower-ecological-footprint alternative to conventional chemicals, aiming to help farmers boost yields sustainably. With fresh Series A capital, IBI Ag plans to accelerate product development and advance regulatory filings on multiple bio-insecticide candidates. The company also intends to deepen its collaboration with strategic investor Corteva to speed commercialization. Founded by The Trendlines Group alongside Dr. Amir Ayali and Dr. Rony Oren Benaroya, IBI Ag has been supported by the Israel Innovation Authority since inception. Financial details beyond the recent $10 million raise were not disclosed.

Total raised

$10M

Funding rounds

1

Latest round

Series A

Latest activity

Nov 2025